Search results
The Pfizer–BioNTech COVID-19 vaccine is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus, by eliciting an immune response to the S antigen. [ 1 ] [ 2 ] [ 31 ] [ 40 ] The vaccine is used to reduce morbidity and mortality from COVID-19.
11 gru 2020 · COMIRNATY ® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech. It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older; It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:
22 sie 2024 · August 22, 2024. Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent...
28 sie 2024 · Pfizer-BioNTech COVID-19 Vaccine is indicated for individuals 5 through 11 years of age (via a 10mcg / 0.3mL single-dose vial presentation) and for individuals 6 months through 4 years of age (via a 3mcg / 0.3mL multi-dose vial (3 doses per vial) presentation).
25 cze 2022 · Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron.
4 paź 2021 · EMA’s human medicines committee (CHMP) has concluded that an extra dose of the COVID-19 vaccines Comirnaty (BioNTech/Pfizer) and Spikevax (Moderna) may be given to people with severely weakened immune systems, at least 28 days after their second dose.
1 wrz 2022 · These vaccines are adapted versions of the original vaccines Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) to target the Omicron BA.1 subvariant in addition to the original strain of SARS-CoV-2. Vaccines are adapted (i.e., updated) to better match the circulating variants of SARS-CoV-2.
